Short answer
Anika Therapeutics, Inc. (ANIK) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers). Q1 2025 earnings press release issued; full results in Exhibit 99.1.
Anika Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2025 earnings press release issued; full results in Exhibit 99.1
- Filing structured as Reg FD-compliant disclosure; not subject to Section 18 liability
Item 5.02 · Departure/Election of Directors or Officers
- EVP, General Counsel & Corporate Secretary Colleran departing May 1, 2026: key legal leadership exit with succession risk
- Through May 1, Colleran retains current salary/benefits and equity continues vesting, but no vacation accrual
- Severance tied to ERA (Dec 12, 2024) Sections 4(b) or 5(b): specific payout amount not disclosed, contingent on clean separation
- Colleran provided general release of claims, limiting future litigation exposure for ANIK
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Anika Therapeutics, Inc. 8-K filings
Get the next ANIK 8-K as it lands
Follow ANIK for push alerts, or ask the research agent what this filing means.